New Patent Cover IL-23R Orally Stable Peptide Inhibitors Including Protagonist’s PTG-200 to Treat IBD

New Patent Cover IL-23R Orally Stable Peptide Inhibitors Including Protagonist’s PTG-200 to Treat IBD
Protagonist Therapeutics has secured a patent covering orally stable peptide inhibitors of the interleukin-23 receptor (IL-23R), including its lead candidate drug PTG-200. The patent protects PTG-200's formulation as well the use of this class of inhibitors to treat inflammatory bowel disease (IBD). The patent provides intellectual property coverage until 2035, David Liu, Protagonist's chief scientific officer and head of research and development, said in a press release. Protagonist, based in Milpitas, California, focuses mainly on developing small molecule drugs which specifically block biological pathways that are currently targeted by marketed injectable antibody drugs. PTG-200 was designed based on this approach to change existing treatment strategies for moderate-to-severe Crohn’s disease. It is currently in Investigational New Drug (IND) enabling studies. "Inhibition of the IL-23 pathway is an effective therapeutic treatment for IBD, as evidenced by a marketed injectable antibody drug for treatment of Crohn's disease," said Liu. "PTG-200 is an oral IL-23R antagonist and is designed to offer potential advantages such as improved convenience, patient compliance, safety, tolerability and access to the targeted IL-23 receptors that are highly expressed in the gut associated lymphoid tissue.| Results from preclinical studies 
Subscribe or to access all post and page content.